Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
Colorcon
McKesson
AstraZeneca

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR DITROPAN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ditropan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00269750 ↗ A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. Completed Alza Corporation, DE, USA Phase 3 1996-07-01 The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.
NCT00293839 ↗ Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder Completed Alza Corporation, DE, USA Phase 3 1969-12-31 The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.
NCT00338624 ↗ An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms. Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Phase 3 2004-05-01 The purpose of this study is to evaluate the safety and effectiveness of oxybutynin extended release tablets 10 mg plus tamsulosin HCl 0.4 mg in the treatment of lower urinary tract symptoms as measured by change of the total International Prostate Symptom Score (I-PSS) from baseline to Week 12 or the Final Visit.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ditropan

Condition Name

Condition Name for Ditropan
Intervention Trials
Healthy 6
Overactive Bladder 5
Hot Flashes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ditropan
Intervention Trials
Urinary Bladder, Overactive 6
Urinary Incontinence 3
Enuresis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ditropan

Trials by Country

Trials by Country for Ditropan
Location Trials
United States 21
Canada 3
Iran, Islamic Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ditropan
Location Trials
West Virginia 3
North Dakota 3
District of Columbia 1
Illinois 1
Iowa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ditropan

Clinical Trial Phase

Clinical Trial Phase for Ditropan
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ditropan
Clinical Trial Phase Trials
Completed 16
Recruiting 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ditropan

Sponsor Name

Sponsor Name for Ditropan
Sponsor Trials
Mylan Pharmaceuticals 6
Pfizer 3
Stéphane Bolduc 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ditropan
Sponsor Trials
Industry 15
Other 10
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Johnson and Johnson
Merck
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.